Singletoncantrell6813

035, 95% CI 1.0, 25.0) from baseline to last observation. When stratified by pediatric versus adult patients, there was improvement in BOT-2 total point score in patients less then 18 years (mean percent increase from baseline to last observation 23%) compared to adults (mean decrease of -0.7%). Subtest analysis of individual BOT-2 items captured some improvement following velmanase alfa treatment in pediatric patients. Conclusions There was limited ability to assess the BOT-2 change responses in adults. Pediatric patients showed stability or improvement in scaled scores relative to healthy peers, indicating continued skill acquisition, which may increase independence and contribute to improved patient quality of life. © 2020 The Authors.Purpose The Coronavirus disease 2019 (COVID-19) reminds us of the SARS outbreak in 2003, and up to date, corticosteroid is commonly administrated to severe patients with COVID-19. Osteonecrosis of the femoral head (ONFH) is a common disabling complication among convalescent SARS patients who received corticosteroid therapy. In China, a considerable number of convalescent SARS patients with steroid-associated ONFH had undergone conservative treatment by Traditional Chinese Medicine (TCM), and this study aims to evaluate the long-term results of a spleen-invigorating Huo-Gu Formula (HGF) therapy in these patients. Participants and methods A total of 33 convalescent SARS patients (nine males and 24 females) with bilateral steroid-associated ONFH (66 hips) were enrolled in this study. All patients received oral HGF therapy for six months when they were confirmed the diagnosis of steroid-associated ONFH. They had been regularly followed up at an interval of one year. Harris hip score and medical imaging modalities be therefore a good alternative for the treatment of steroid-associated ONFH secondary to rheumatologic and infection diseases. © 2020 The Author(s).I start with a brief survey of paradigms in Chemical Engineering to highlight that in the early 70 s my thesis advisor P. Quinine chemical structure Le Goff already mentioned the strong link of chemical processes with Environment, Energy and Economy (Market). Then I move to my vision of ChE today summarized in ChE = M2P2E (Molecular, Materials, Process and Product Engineering). I describe how I built a research lab centered around Cyclic Adsorption/Reaction Processes focusing in adsorption technologies to help solving environmental problems. I stress the basic concepts of adsorption processes and the need to use proper diffusion models for intraparticle mass transfer instead of pseudo first order or second order kinetic models. I also consider that adsorbent metrics should be linked to the process where the material is used materials and processes together! In the last section I review some challenging areas where adsorption technologies are useful. Carbon Capture and Utilization involving Pressure Swing Adsorption to capture CO2 from flue gas in a pilot plant, 3D printed composite monoliths for Electric Swing Adsorption, and Utilization of CO2 to be transformed in methanol or Synthetic Natural Gas (SNG) (Power-to-Gas concept). I also address the general topic "Processing of diluted aqueous solutions" with special attention for the development of Simulated Moving Bed coupled with Expanded Bed Adsorption. Finally the integrated process to produce high-added valued compounds (vanillin and syringaldehyde) from Kraft lignin is shown as an example of Lignin valorization in pulp mill biorefinery. © 2020 Elsevier Ltd. All rights reserved.Introduction Interstitial lung disease (ILD) is a frequent extra-articular manifestation of Rheumatoid arthritis (RA), but nowadays there are no randomized controlled clinical trials to support therapeutic guidelines. RA-ILD, especially with UIP pattern, shares some similarities with idiopathic pulmonary fibrosis, suggesting a possible role of antifibrotic therapy in these patients. To date, there are no published data supporting the use of pifenidone in RA-ILD.We describe for the first time two patients with a diagnosis of RA-ILD successfully treated with hydroxychloroquine and pirfenidone, without adverse events. Case presentation Patient 1 and patient 2 were first diagnosed with IPF (UIP pattern at high-resolution computed tomography, no other signs or symptoms suggesting other forms of ILD, routine laboratory examinations and immunological texts negative). Patients started pirfenidone 2403 mg daily. Few months later, they referred to our multidisciplinary outpatient for arthritis. ACPA and RF were positive. A diagnosis of RA was performed and treatment with corticosteroids and hydroxychloroquine was started, in association with pirfenidone.In both cases we assessed the stabilization of articular and lung manifestations, without adverse events. Discussion In absence of randomized controlled trials, the optimal treatment of RA-ILD has not been determined and remains challenging. When considering therapeutic options for RA-ILD, both pulmonary and extra-thoracic disease manifestations and degrees of activity should be assessed and taken into consideration. Future prospective research might change RA-ILD management, moving to a more personalized approach based on the identification of different phenotypes of the disease or to a combination of immunosuppressive and antifibrotic treatment. © 2020 The Authors. Published by Elsevier Ltd.The current health crisis caused by COVID-19 is a challenge for oncology treatment, especially when it comes to radiotherapy. Cancer patients are already known to be very fragile and COVID-19 brings about the risk of severe respiratory complications. In order to treat patients safely while protecting medical teams, the entire health care system must optimize the way it approaches prevention and treatment at a time when social distancing is key to stemming this pandemic. All indications and treatment modalities must be re-discussed. This is particularly the case for radiotherapy of bone metastases for which it is possible to reduce the number of sessions, the frequency of transport and the complexity of treatments. These changes will have to be discussed according to the organization of each radiotherapy department and the health situation, while medical teams must remain vigilant about the risks of complications of bone metastases, particularly spinal metastases. In this short piece, the members of the GEMO (the European Study Group of Bone Metastases) offer a number of recommendations to achieve the above objectives, both in general and in relation to five of the most common situations on radiation therapy for bone metastases.